BridgeMD
Clinical trial with the drug lorlatinib in patients affected by a lymphoma that expresses the protein ALK, previously treated with ALK inhibitors but for whom the therapy is not anymore effective
EU CTIS ID: 2025-520788-42-00
What this study is testing
Define the objective response rates (ORR) of PF-06463922 in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Female and male patients who are of childbearing potential must agree to use an effective form of contraception (2 forms of contraception) with their partners throughout participation in this study and for at least 90 days after the last dose of treatment
- ALK+ Lymphoma diagnosed by IHC or FISH
- Patiets with prior exposure to Brentuximab are eligible for inclusion. The use of Brentuximab is permitted either as first-line or as a subsequent therapy. Refractory/resistant disease is defined as either (i) no achievement of CR or PR during or at the end of at least one prior line of cytotoxic chemotherapy and one prior ALK inhibitor, or (ii) documented progression occurring within 6 months from completion of such treatments
- Any prior antitumor medical treatment or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values. Systemic anticancer therapy completed within a minimum of 5 half-lives of study entry
You likely can't join if
- Current treatment on another therapeutic clinical trial
- Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration
- Clinically significant cardiovascular disease (that is, active or <3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class = II)
- Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2: second-degree or third-degree AV block (unless paced) or any AV block with PR >220 msec, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc >470 msec, or congenital long QT syndrome
- Pregnancy or breastfeeding
- Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates
See the full eligibility criteria
Who can join
- Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Female and male patients who are of childbearing potential must agree to use an effective form of contraception (2 forms of contraception) with their partners throughout participation in this study and for at least 90 days after the last dose of treatment
- ALK+ Lymphoma diagnosed by IHC or FISH
- Patiets with prior exposure to Brentuximab are eligible for inclusion. The use of Brentuximab is permitted either as first-line or as a subsequent therapy. Refractory/resistant disease is defined as either (i) no achievement of CR or PR during or at the end of at least one prior line of cytotoxic chemotherapy and one prior ALK inhibitor, or (ii) documented progression occurring within 6 months from completion of such treatments
- Any prior antitumor medical treatment or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values. Systemic anticancer therapy completed within a minimum of 5 half-lives of study entry
- Able to take oral therapy
- Female or male, 18 years of age or older
- ECOG performance status 0-3
- Adequate organ function as defined by the following criteria: - Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) = 2.5 x upper limit of normal (ULN) or AST and ALT = 5 x ULN if liver function abnormalities are due to underlying malignancy - Total serum bilirubin 1.5 x ULN (except patients with documented Gilbert’s syndrome - Creatinine = 1.5 x ULN
- Adequate bone marrow function: - Absolute neutrophil count (ANC) = 1000/μL - Platelets = 50.000/μL - Hemoglobin = 9.0 g/dL The hematological values will not be considered in case of bone marrow involvement
What rules you out
- Current treatment on another therapeutic clinical trial
- Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration
- Clinically significant cardiovascular disease (that is, active or <3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class = II)
- Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2: second-degree or third-degree AV block (unless paced) or any AV block with PR >220 msec, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc >470 msec, or congenital long QT syndrome
- Pregnancy or breastfeeding
- Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates
- Prior malignancy other than basal cell carcinoma , if original diagnosis happened in the last 5 years
- Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (e.g. uncontrolled hyperglycemia, current gallstone disease, alcoholism)
- Hypertriglyceridemia ≥ Grade 2, in order to avoid excluding patients with only mild metabolic alterations
- Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.